Pegaspargase
- Generic Name
- Pegaspargase
- Brand Names
- Oncaspar
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 130167-69-0
- Unique Ingredient Identifier
- 7D96IR0PPM
- Background
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synt...
- Indication
Pegaspargase is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with 1) first-line acute lymphoblastic leukemia or 2) acute lymphoblastic leukemia and hypersensitivity to asparaginase.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma
- First Posted Date
- 2013-08-13
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT01921790
- Locations
- 🇨🇳
Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT01920737
- Locations
- 🇺🇸
Weill Cornell Medical Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 18
- Registration Number
- NCT01769209
- Locations
- 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- Drug: dexamethasoneDrug: vincristine sulfateBiological: rituximabDrug: clofarabineDrug: cyclophosphamideDrug: etoposideBiological: aldesleukinDrug: pegaspargaseDrug: methotrexateDrug: mercaptopurineDrug: cytarabineDrug: mitoxantroneDrug: teniposideDrug: vinblastineBiological: natural killer cell infusionOther: laboratory biomarker analysisProcedure: allogeneic hematopoietic stem cell transplantationDrug: therapeutic hydrocortisoneDevice: CliniMACS
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT01700946
- Locations
- 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL
- Conditions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT01523977
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸UCSF, San Francisco, California, United States
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2020-10-27
- Target Recruit Count
- 23
- Registration Number
- NCT01483690
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇦🇺Children's Hospital at Westmead, Westmead, New South Wales, Australia
🇦🇺Sydney Children's Hospital, Sydney, Australia
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT01451515
- Locations
- 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT01403415
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸C S Mott Children's Hospital, Ann Arbor, Michigan, United States
Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2011-03-28
- Last Posted Date
- 2017-08-07
- Target Recruit Count
- 14
- Registration Number
- NCT01324180
- Locations
- 🇺🇸
Holtz Children's Hospital University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸Arnold Palmer Hospital for Children, Orlando, Florida, United States
🇺🇸All Children's Hospital, Saint Petersburg, Florida, United States
Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL
- Conditions
- Interventions
- Drug: AmsacrineDrug: CyclophosphamideDrug: ClofarabineDrug: CytarabineDrug: DexamethasoneDrug: Daunorubicin hydrochlorideDrug: Doxorubicin hydrochlorideDrug: Etoposide phosphateDrug: MercaptopurineDrug: MethotrexateDrug: MethylprednisoloneDrug: PegaspargaseDrug: ThioguanineDrug: Vincristine sulfateRadiation: Whole-brain radiation therapy
- First Posted Date
- 2010-10-26
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 745
- Registration Number
- NCT01228331
- Locations
- 🇩🇪
Universitaetsklinikum Duesseldorf, Duesseldorf, Germany
🇩🇪University Medical Center Hamburg - Eppendorf, Hamburg, Germany
🇩🇪Johannes Gutenberg University, Mainz, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.